Education
About Us
Working with TipRanks
Follow Us
Notable Labs, Ltd. (NTBLQ)
:NTBLQ
NTBLQ Stock Chart & Stats
$0.02
<$0.01(30.43%)
At close: 4:00 PM EST
$0.02
<$0.01(30.43%)
Day’s Range― - ―
52-Week Range$0.01 - $0.06
Previous CloseN/A
Volume3.06K
Average Volume (3M)28.14K
Market Cap
$10.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-52.35
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,659,496
10 Day Avg. Volume43,656
30 Day Avg. Volume28,136
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.56
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentNotable Labs kicked off the volasertib AML trial with an accelerated clinical program moving directly into the Predictive Precision Medicines Platform-selected Phase 2 trial.
Innovation And TechnologyNotable Labs' ability to now use cryopreserved samples with its Predictive Precision Medicines Platform unlocks significant data sources.
Regulatory ProgressNTBL was cleared for the Phase 2 volasertib program by the FDA and intends to enroll patients.
Bears Say
Financial HealthThe company had a 2Q-end cash balance of $4.1M, and the estimated current cash balance is approximately $2M.
Operational ChallengesNotable Labs is conserving cash by pausing the planned volasertib Phase 2 trial and reducing workforce and consultants by 65%.
Uncertainty In Product DevelopmentThe future of lead asset volasertib is unclear.
NTBLQ FAQ
What was Notable Labs, Ltd.’s price range in the past 12 months?
Notable Labs, Ltd. lowest stock price was $0.01 and its highest was $0.06 in the past 12 months.
What is Notable Labs, Ltd.’s market cap?
Notable Labs, Ltd.’s market cap is $10.00.
When is Notable Labs, Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Notable Labs, Ltd.’s earnings last quarter?
Currently, no data Available
Is Notable Labs, Ltd. overvalued?
According to Wall Street analysts Notable Labs, Ltd.’s price is currently Overvalued.
Does Notable Labs, Ltd. pay dividends?
Notable Labs, Ltd. does not currently pay dividends.
What is Notable Labs, Ltd.’s EPS estimate?
Notable Labs, Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Notable Labs, Ltd. have?
Notable Labs, Ltd. has 9,659,496 shares outstanding.
What happened to Notable Labs, Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Notable Labs, Ltd.?
Currently, no hedge funds are holding shares in NTBLQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Notable Labs, Ltd.
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.
Technical Analysis
Enveric Biosciences
―
Revelation Biosciences
―
Dermata Therapeutics
―
Psyence Biomedical
―
Azitra Inc
―
Ownership Overview
―
Insiders
3.49% Other Institutional Investors
96.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---